PF-Atlas › Clinical Trials › NCT02171156

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis

nintedanib · Not specified

Registry ID
NCT02171156
Phase
Not specified
Status
Approved For Marketing
Drug / intervention
nintedanib
Sponsor
Boehringer Ingelheim
Locations
7

About this trial

To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF).

View NCT02171156 on ClinicalTrials.gov →

Explore related

All nintedanib trialsAll IPF trials

Related trials

nintedanib — NCT02606877Nintedanib — NCT02598193Nintedanib — NCT02579603Nintedanib — NCT02597933Nintedanib — NCT02999178Nintedanib — NCT02607722
Medical disclaimer. This page summarizes public trial data for NCT02171156 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.